Navigation Links
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Date:9/4/2007

d development activities; the results of pre- clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as amended, and the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2007. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2007 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MUMBAI , Indien, August 1, 2014 ... ("Cipla") und BioQuiddity Inc. gaben heute bekannt, ... in regionalen Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen ... die das Gebiet der Europäischen Union und ... mit CE-Kennzeichnung versehene und mit Ropivacain gefüllte ...
(Date:7/31/2014)... IRIDEX Corporation (Nasdaq: IRIX ) today reported financial ... 28, 2014.  , Revenues were $10.6 million in ... in the 2013 second quarter and up sequentially from $10.3 ... first six months of 2014 were $20.9 million, up 15% ... year. , Gross margin for the quarter was 50.0%, ...
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28
... 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... that Valeant,s subsidiaries, Valeant Pharmaceuticals North America LLC ... signed an agreement to acquire the assets of ...  Valeant will pay Janssen $345 million for the ...
... Aethlon Medical, Inc., (OTCBB: AEMD) disclosed today that ... the following letter to shareholders. (Photo: ... Last December, I authored a shareholder letter which ... need for innovative new therapeutic strategies to evolve as ...
Cached Medicine Technology:Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics 2Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics 3Aethlon Medical Releases Shareholder Letter 2Aethlon Medical Releases Shareholder Letter 3Aethlon Medical Releases Shareholder Letter 4
(Date:8/1/2014)... Frontier Nursing University has been awarded ... Advanced Education Nursing Traineeship (AENT) program . This ... to 280 students over the grant period. ... increase the number of advanced education nurses trained to ... address the nurse faculty shortage that inhibits nursing schools ...
(Date:8/1/2014)... New York City, NY (PRWEB) August 01, 2014 ... need for two incomes, and the convenience of processed, microwavable ... obesity epidemic. Diet Doc does not offer patients a mere ... serious about helping everyone, in any part of the country, ... believes that if they offer patients the tools and education ...
(Date:8/1/2014)... MA (PRWEB) August 01, 2014 For ... even when memory is still within the normal range, ... warning signs of future decline. This merits a closer ... in the August 2014 Harvard Men's Health Watch ... that if they forget where their keys are they ...
(Date:8/1/2014)... BellasDress has recently showcased its beautifully made ... gorgeous styles. The company’s lot of hot styles, including ... one shoulder chiffon outfits and high low outfits. Now, ... purple prom dresses. As one of the most suppliers ... quality. Thus, all its items are of superb quality; ...
(Date:8/1/2014)... Tara Haelle HealthDay ... A home-packed lunch isn,t necessarily healthier than school cafeteria fare, ... just 27 percent of the lunches third and fourth graders ... Program (NSLP) standards. , , "Our findings are similar to ... the world, which have found that high-calorie packaged foods and ...
Breaking Medicine News(10 mins):Health News:Frontier Nursing University Receives $700,000 in Scholarships for Advanced Practice Nursing and Midwifery Students 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 3Health News:Worried About Changes in Your Memory? It's Worth A Closer Look, From the August 2014 Harvard Men's Health Watch 2Health News:BellasDress Creates Must-have Purple Prom Dresses for Prom Attendees 2Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 2Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 3
... disorder (ADHD) is one of the most common mental ... are excessively restless, impulsive, and distractible and experience difficulties ... a common theme for ADHD symptoms. These symptoms ... a combination of the two. In a ...
... number of women delaying motherhood until their 40s grows, CDC ... going up in both 2005 and 2006, the number of ... 2008, federal health officials report. , On the other hand, ... life, with a big jump in births for women in ...
... Human Touch Massage ... , ... 6, 2010 -- Human Touch , the U.S. market leader of innovative massage chairs, ... Federation of Chiropractic (WFC) for its massage chairs as a valid supplement to back-care therapies. ...
... is available in German . This ... Forschungsgemeinschaft (DFG, German Research Foundation) and the Donors, Association ... (Stifterverband fr die Deutsche Wissenschaft) goes to cell physiologist ... professor at Bochum,s Ruhr University for his many years ...
... ... “Federal Cyber Security Outlook for 2010” Provides In-Depth Dive into Endpoint Management and Cyber ... ... new Clarus Research Group survey commissioned by Lumension , nearly three-quarters of federal ...
... sedatives up 65 percent in U.S., study finds , ... accidental and intentional abuse of prescription sedatives, tranquilizers and ... decade, new research reveals. , Hospital stays from an ... and sedatives (such as Valium and Ativan) jumped 37 ...
Cached Medicine News:Health News:Synergy between behavioral and pharmacologic interventions for ADHD 2Health News: U.S. Teen Birth Rate Drops 2Health News: U.S. Teen Birth Rate Drops 3Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 2Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 3Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 4Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 5Health News:Communicator Award 2010 goes to Hanns Hatt 2Health News:Communicator Award 2010 goes to Hanns Hatt 3Health News:New Study Reveals National IT Security Challenges Mounting; Growing Sophistication of Cyber Attacks Pose Greatest Risk to U.S. Infrastructure 2Health News:New Study Reveals National IT Security Challenges Mounting; Growing Sophistication of Cyber Attacks Pose Greatest Risk to U.S. Infrastructure 3Health News:New Study Reveals National IT Security Challenges Mounting; Growing Sophistication of Cyber Attacks Pose Greatest Risk to U.S. Infrastructure 4Health News:New Study Reveals National IT Security Challenges Mounting; Growing Sophistication of Cyber Attacks Pose Greatest Risk to U.S. Infrastructure 5Health News:New Study Reveals National IT Security Challenges Mounting; Growing Sophistication of Cyber Attacks Pose Greatest Risk to U.S. Infrastructure 6Health News:Prescription Drug Abuse Sending More to Hospitals 2Health News:Prescription Drug Abuse Sending More to Hospitals 3
Standard Deflectable Catheters...
Fixed and steerable lumen diagnostic mapping catheters are offered in a variety of catheter configurations...
The Polaris-DX steerable diagnostic catheter is designed for comfort and ergonomic handling during mapping procedures....
Sophisticated DecaPolar Catheters provide enhanced recording and mapping quality....
Medicine Products: